Liquidia (LQDA) News Today

Liquidia Corporation (NASDAQ: LQDA) has been supported by strong YUTREPIA commercial momentum, better-than-expected revenue and bullish analyst revisions. Investors are also weighing the impact of a large charge that drove a reported quarterly loss, along with some cautious views on valuation.

• Positive Sentiment: Third-quarter revenue reached $225.3 million, up 314.9% year over year and ahead of expectations, with YUTREPIA sales of $222.7 million. The earnings coverage highlights strong product demand; a large charge obscured the reported loss, while adjusted results beat estimates. LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales
• Positive Sentiment: Management reported record October shipments and expanding PAH adoption, suggesting demand continued after the quarter. The post-settlement market outlook may also help Liquidia pursue growth, although referral disruptions remain a consideration. LQDA Q3 Earnings Call Highlights Growth and Post-Settlement Outlook
• Positive Sentiment: Raymond James upgraded LQDA to “strong buy” and raised its price target to $77 from $53. Needham raised its target to $66 and maintained “buy,” while BTIG raised its target to $87 and also maintained “buy.” Raymond James upgrades Liquidia on YUTREPIA launch
• Neutral Sentiment: Commercial growth is encouraging, but the company noted referral disruptions amid market changes, which could affect the pace of adoption. Earnings call outlook
• Negative Sentiment: Reported GAAP results included a $389.7 million charge, producing a substantial quarterly loss despite strong revenue and adjusted earnings performance. Wells Fargo raised its target to $40 but kept an “equal weight” rating, signaling a more cautious view at the current valuation. A charge masks a booming YUTREPIA quarter